% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Flies:1023537,
author = {Flies, Christina Maria and Friedrich, Michel and Lohmann,
Philipp and van Garderen, Karin Alida and Smits, Marion and
Tonn, Joerg-Christian and Weller, Michael and Galldiks,
Norbert and Snijders, Tom Jan},
title = {{T}reatment-associated imaging changes in newly diagnosed
{MGMT} promoter-methylated glioblastoma undergoing
chemoradiation with or without cilengitide},
journal = {Neuro-Oncology},
volume = {26},
number = {5},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {FZJ-2024-01743},
pages = {902-910},
year = {2024},
abstract = {Background: Radiological progression may originate from
progressive disease (PD) or
pseudoprogression/treatment-associated changes. We assessed
radiological progression in MGMT promoter-methylated
glioblastoma treated with standard-of-care chemoradiotherapy
with or without the integrin inhibitor cilengitide according
to the modified RANO criteria of 2017.Methods: Patients with
≥3 follow-up MRIs were included. Preliminary PD was
defined as a $≥25\%$ increase of the sum of products of
perpendicular diameters (SPD) of a new or increasing lesion
compared to baseline. PD required a second $≥25\%$
increase of the SPD. Treatment-associated changes required
stable or regressing disease after preliminary PD.Results:
Of the 424 evaluable patients, 221 patients $(52\%)$ were
randomized into the cilengitide, and 203 patients $(48\%)$
into the control arm. After chemoradiation with or without
cilengitide, preliminary PD occurred in 274 patients
$(65\%)$ during available follow-up, and 88 of these
patients $(32\%)$ had treatment-associated changes, whereas
67 patients $(25\%)$ had PD. The remaining 119 patients
$(43\%)$ had no further follow-up after preliminary PD.
Treatment-associated changes were more common in the
cilengitide arm than in the standard-of-care arm $(24\%$ vs.
$17\%;$ relative risk, 1.3; $95\%$ confidence interval,
1.004-1.795; p=0.047). Treatment-associated changes occurred
mainly during the first six months after RT $(54\%$ after
three months vs. $13\%$ after six months).Conclusion: With
the modified RANO criteria, the rate of treatment-associated
changes was low compared to previous studies in MGMT
promoter-methylated glioblastoma. This rate was higher after
cilengitide compared to standard-of-care treatment.
Confirmatory scans, as recommended in the modified RANO
criteria, were not always available reflecting current
clinical practice.Keywords: glioma; modified RANO criteria;
pseudoprogression; temozolomide.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {38219019},
UT = {WOS:001154554300001},
doi = {10.1093/neuonc/noad247},
url = {https://juser.fz-juelich.de/record/1023537},
}